Life Science Compliance Update

May 26, 2016

NIH Asks for Input on NCAB Cancer Moonshot Blue Ribbon Panel

Recently, the National Institutes of Health (NIH) released a Request for Information (RFI), asking for both public and cancer research community input on the National Cancer Advisory Board (NCAB) Blue Ribbon Panel. The Blue Ribbon Panel is part of the National Cancer Moonshot Initiative, which is led by Vice President Joe Biden and aims to make more cancer therapies available, while continuing to improve cancer prevention and early detection. Additional details of the National Cancer Moonshot Initiative can be found at

The purpose of the NCAB is to ensure that the National Moonshot Initiative's goals and approaches are grounded in solid science. The Blue Ribbon panel is a panel of experts assembled to guide the NCAB's work and is composed of leading experts from a broad range of scientific areas including biology, immunology, genomics, diagnostics, bioinformatics, and cancer prevention and treatment. The panel does not just include researchers, however, it also includes clinicians and nurses, as well as representatives of cancer advocacy organizations and the pharmaceutical and biotechnology industries.

NIH is seeking community input to help "enable the Blue Ribbon Panel to consider a wide range of input from researchers, scientists, physicians, advocates, students, data scientists, and members of the public." They are requesting input in the following specific areas: expanding clinical trials; enhanced data sharing; cancer immunology and prevention; implementation sciences; pediatric cancer; precision, prevention, and early detection; and tumor evolution and progression.

The request for information is for planning purposes only and should not be construed as a solicitation for applications or proposals, or as an obligation on the part of the United States federal government.

If you have any questions about this particular RFI, you can contact Kelli Marciel at the National Cancer Institute at 9609 Medical Center Drive, Bethesda, MD 20892-9760,, or (301) 594-3330.

NIH is asking for responses to be submitted to either the National Cancer Institute (NCI) or NIH before July 1, 2016 at 5:00 pm EST. Responses can be submitted electronically through the online platform or via email to While electronic responses are preferred, non-electronic responses can be accepted by calling the NCI Cancer Information Service at (800) 422-6237, or by mail to Blue Ribbon Panel, National Cancer Moonshot Initiative, National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD 20892-9760.


July 06, 2015

NIH approves strategic vision to transform National Library of Medicine


The National Institutes of Health (NIH) Director Francis S. Collins, M.D., Ph.D., recently approved a federal report that describes the scientific vision for the NIH’s National Library of Medicine (NLM), the world’s largest biomedical library. Early in 2015, Dr. Collins tasked a working group of his Advisory Committee to the NIH Director (ACD), to create a strategic vision for the NLM. The ACD is comprised of experts in the fields of biomedical research, bioinformatics, library sciences, publishing, and patient care. The working group assessed the current mission, organization, and programmatic priorities of the NLM.

The report’s executive summary lists six recommendations from the ACD to guide the future of the NLM and notably it does not recommend that anything be cut:

(1)  Continually evolve to remain a leader in assimilating and disseminating accessible and authoritative biomedical research findings and trusted health information to the public, healthcare professionals, and researchers worldwide.

(2)  Lead efforts to support and catalyze open science, data sharing, and research reproducibility, striving to promote the concept that biomedical information and its transparent analysis are public goods.

(3)  Be the intellectual and programmatic epicenter for data science at NIH, including becoming the center of intellectual and programmatic activities in biomedical data science, and stimulate its advancement throughout biomedical research and application.

(4)  Strengthen its role in fostering the future generation of professionals in biomedical informatics, data science, library sciences, and related disciplines through sustained and focused training efforts.

(5)  Maintain, preserve, and make accessible the nation’s historical efforts in advancing biomedical research and medicine, thereby ensuring that this legacy is both safe and accessible for long-term use.

(6)  Have new NLM leadership evaluate what talent, resources, and organizational structures are required to ensure NLM can fully achieve its mission and best allocate its resources.

The report also acknowledges the challenges faced by the NLM. The ACD notes that future of biomedical research will require an expanded role for data science and the expertise of the NLM. This is happening in conjunction with ongoing budget constraints. Short of directly calling for additional funding, the ACD instead believes the NLM will need to maximize efficiency of existing resources, citing “care consideration and strategic planning” as essential for NLM to maintain and likely expand its role.

The ACD concluded its recommendations, writing that it believes the “NLM must evolve to seize this critical moment in biomedical history and be a trustworthy source of biomedical data and information, an advocate for open science, a promoter of the next generation of data scientists, a protector of the legacy of the past, and a vital partner for those who are generating biomedical knowledge for the future.”

Dr. Collins accepted the ACD recommendations in full, but acknowledged that NIH will need to consider the requirements and infrastructure implications for centering NIH’s biomedical data science activities within the NLM. In addition, NIH has launched a nationwide search for the director of the NLM to replace Donald Lindberg, M.D., who served as the NLM director for more than 30 years and retired in March 2015. The next director will need to conduct a thorough review and decide which programs “should be expanded or stopped,” according to the ACD report.


June 05, 2015

NIH Halts Drug Making Operations after FDA Inspection

Today, the National Institutes of Health (NIH) was ordered to halt drug making operations after a fungal contamination potentially affected 46 clinical studies. In April, two vials of albumin, which is used for administration of the drug interleukin in experimental studies, were found to be contaminated with fungus. As it has been reported, vials from the same batch had been administered to six patients. The patients have been notified and are being monitored for the development of infection.

The FDA's inspection report can be found here. It reads as a heavy indictment of the NIH facility. 17 specific observations are listed, describing the NIH's lack of compliance with the government's own standards. For example, FDA writes "an operator was observed processing sterile drug products with an exposed wrist from a gap between their gloves and their gown. The same operator had exposed facial hair."

The Washington Post lists a number of other FDA concerns, including no filter or screen covering a vent into a laboratory "clean room." Insufficient documentation about the cleaning of the facility. Insects found in a pair of ceiling light bays in clean rooms. Employees not wearing protective apparel. A water system that could harbor "microbial proliferation." Inspectors found that the facilities themselves were "not designed and controlled to prevent contamination risks to sterile drugs."

According to the NIH release, the following steps are being taken immediately to protect patients:

Operations of The Pharmaceutical Development Section have been suspended and no products will be made or distributed until all problems are fully understood and corrected. Materials produced by the Section are being systematically tested for contamination.

Of the participants in the 46 studies that are potentially affected, approximately 250 are currently scheduled to receive products manufactured by the PDS. NIH has notified the individual principal scientists responsible for each of those protocols, and is in the process of notifying the participants in these protocols. The vast majority of these patients are not immediately due for treatment and NIH is working to secure alternative sources for the products.


An external group of experts in microbiology and sterile manufacturing practices will be appointed to conduct a thorough review, including an assessment of all standard operating procedures, policies, staffing, and training, and make recommendations to the NIH director on the corrective actions required.

 In addition to the immediate steps NIH is taking, it will provide an interim corrective action plan to the FDA by Friday, June 19, 2015.

“This is a distressing and unacceptable situation,” said NIH Director Francis S. Collins, M.D., Ph.D. “The fact that patients may have been put in harm’s way because of a failure to follow standard operating procedures in the NIH Clinical Center’s Pharmaceutical Development Section is deeply troubling. I will personally oversee the steps to protect the safety of patients and remedy the situation as swiftly as possible.”


This event is reminiscent of the FDA's New England Compounding Center inspection controversy. FDA's inspectors observed problems with NECC's ability to maintain its clean room, which is the enclosed space that is designed and maintained to have a controlled environment with low levels of airborne particles and surface contamination. In that case The U.S. Centers for Disease Control and Prevention (CDC) reported that 751 patients in 20 states were diagnosed with a fungal infection after receiving injections from the NECC. Of those 751 patients, the CDC reported that 64 patients in nine states died.

The closure is a good example just how difficult and costly it is to produce pharmaceutical grade products.  Pharmaceutical and biologic manufacturing requires skill sets and often overtime commitments that don't match government's skills and experience.  This serves as an example to academics and Pharmascolds that the government is not capable of doing everything and needs the pharmaceutical industry to do what they do best.

Francis Collins has to take responsibility for the mess.  He announced he is personally overseeing this.   But the best use of his time may be in finding alternative manufacturing then quickly returning to focus on developing cures.  In the future NIH should consider contracting the manufacturing to facilities near NIH.  Maryland has a robust Biotech Corridor which has extensive manufacturing experience and familiarity with FDA inspections and procedures.


Preview | Powered by FeedBlitz


August 2016
Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31